Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Company Profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6770

Website: pliantrx.com

Address:

331 Oyster Point Boulevard, South San Francisco, United States

Stef_DL Jun. 28 at 8:27 PM

$PLRX I have been wondering that myself. AI says: --- Pipeline Advancement: Progress and favorable safety/efficacy data from the ongoing FORTIFY trial, which is evaluating PLN-101095 in patients with immune-checkpoint-inhibitor (ICI)-refractory advanced or metastatic solid tumors. Strategic Partnerships & Buyouts: As a clinical-stage, pre-revenue company, securing a major pharmaceutical partnership or being acquired would immediately inject capital and validate their integrin-targeting technology platform. Macroeconomic Conditions & Sector Sentiment: Because Pliant is heavily reliant on future financing and trial outcomes, any easing of monetary policy (interest rate cuts) or a broader biotech sector rally would improve capital access and lift the stock. Investors remain cautious due to past trial discontinuations (such as the BEACON-IPF trial), but Pliant maintains enough capital to fund their operations and upcoming data readouts into the second half of 2028. So maybe a bit..?

0 · Reply

CapSampler Jun. 26 at 6:06 PM

$PLRX is there any hope here? Objectively, any potential point or solution for a comeback?

0 · Reply

ka1954 Jun. 25 at 10:36 PM

$PLRX when the fuck will this do something? its been more than a year its stuck

0 · Reply

focafoca99 Jun. 11 at 9:16 PM

$PLRX presented its 2026 annual meeting results, with shareholders electing three directors and ratifying its auditor.

0 · Reply

THSSKS Jun. 4 at 2:57 PM

$PLRX every time they present data, the stock goes down. They’re just going to burn it up. Bunch of greedy bod’s. They need to buy a better pipeline or stop this one asap and announce strategic alternatives

0 · Reply

clan Jun. 1 at 12:36 PM

$AZN ⚠️ Great news for diabetic kiddos ! ! ! 👍👍 FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 🚫💉 No needles! $CPIX $PLRX $GRI

0 · Reply

GangsterX May. 28 at 7:24 PM

$PLRX hold and wait for news before September...

0 · Reply

djcal May. 24 at 4:12 PM

$PLRX $172.40M but subtract the debt load $28.78M leaves you $142.11M and just keeps getting smaller every quarter. Time and them doing nothing but collecting their huge salaries.

0 · Reply

ACInvestorBlog May. 22 at 1:39 PM

$PLRX on high alert for the coming sessions. Still under accumulation.

2 · Reply

ACInvestorBlog May. 21 at 3:53 PM

$PLRX There have been some big buy blocks popping up in the last few days. I reckon we’ll hear news anytime now. The whales are holding substantial positions here. On high alert. Institutional ownership overall: Around 82–97% of the float (high for a small-cap biotech), with roughly 120 institutions holding shares. Tang Capital is by far the largest holder and has been increasing its position.

0 · Reply

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 19, 2026, 11:30 AM EDT - 6 weeks ago

Pliant Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-11T20:57:49.000Z - 7 weeks ago

Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)

May 11, 2026, 4:05 PM EDT - 7 weeks ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Pliant Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Pliant Therapeutics Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 2 months ago

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

2026-04-30T13:41:08.000Z - 2 months ago

Pliant Therapeutics doses first participant in FORTIFY expansion trial

$Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors$

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Pliant Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 2 months ago

Pliant Therapeutics Proxy statement: Proxy filing

2026-04-19T17:00:49.000Z - 2 months ago

Pliant announces presentation of updated data from Phase 1 trial of PLN-101095

$Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting$

Apr 18, 2026, 1:31 PM EDT - 2 months ago

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

2026-03-30T22:05:10.000Z - 3 months ago

Pliant Therapeutics files $300M mixed securities shelf

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Pliant Therapeutics Registration statement: Registration filing

Mar 18, 2026, 9:00 AM EDT - 3 months ago

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

2026-03-13T11:10:14.000Z - 4 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Canaccord

2026-03-12T11:10:41.000Z - 4 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler

Mar 11, 2026, 5:00 PM EDT - 4 months ago

Pliant Therapeutics Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 4 months ago

Pliant Therapeutics Earnings release: Q4 2025

2026-03-11T20:27:59.000Z - 4 months ago

Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)

Mar 11, 2026, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Feb 25, 2026, 2:40 PM EST - 4 months ago

Pliant Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:00 AM EST - 4 months ago

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Dec 4, 2025, 12:30 PM EST - 7 months ago

Pliant Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 12:30 PM EST - 7 months ago

Pliant Therapeutics Slides: Piper Sandler 37th Annual Healthcare Conference

2025-12-04T12:35:15.000Z - 7 months ago

Pliant Therapeutics announces interim data from PLN-101095

$Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Dec 4, 2025, 7:30 AM EST - 7 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 1, 2025, 8:30 AM EST - 7 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

2025-11-06T23:45:29.000Z - 8 months ago

Pliant Therapeutics reports Q3 EPS (43c), consensus (52c)

Nov 6, 2025, 4:05 PM EST - 8 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:00 PM EST - 8 months ago

Pliant Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Pliant Therapeutics Earnings release: Q3 2025

2025-10-10T09:05:07.000Z - 9 months ago

Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan

2025-08-10T18:10:14.000Z - 11 months ago

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

2025-08-08T11:16:07.000Z - 11 months ago

Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler

2025-08-07T21:40:19.000Z - 11 months ago

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Pliant Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Pliant Therapeutics Quarterly report: Q2 2025

Jun 27, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF

May 21, 2025, 4:03 PM EDT - 1 year ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

2025-05-08T21:45:41.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c)

2025-05-08T20:50:13.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)

May 8, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Quarterly report: Q1 2025

2025-05-01T21:00:50.000Z - 1 year ago

Pliant Therapeutics to reduce workforce by 45%

May 1, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

2025-03-17T12:10:07.000Z - 1 year ago

Pliant Therapeutics announces interim Phase 1 data from PLN-101095

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

2025-03-13T11:30:56.000Z - 1 year ago

Pliant Therapeutics adopts limited duration stockholder rights agreement

Mar 13, 2025, 7:20 AM EDT - 1 year ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Annual report: Q4 2024

Mar 3, 2025, 9:27 AM EST - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Stef_DL Jun. 28 at 8:27 PM

0 · Reply

CapSampler Jun. 26 at 6:06 PM

$PLRX is there any hope here? Objectively, any potential point or solution for a comeback?

0 · Reply

ka1954 Jun. 25 at 10:36 PM

$PLRX when the fuck will this do something? its been more than a year its stuck

0 · Reply

focafoca99 Jun. 11 at 9:16 PM

$PLRX presented its 2026 annual meeting results, with shareholders electing three directors and ratifying its auditor.

0 · Reply

THSSKS Jun. 4 at 2:57 PM

0 · Reply

clan Jun. 1 at 12:36 PM

0 · Reply

GangsterX May. 28 at 7:24 PM

$PLRX hold and wait for news before September...

0 · Reply

djcal May. 24 at 4:12 PM

$PLRX $172.40M but subtract the debt load $28.78M leaves you $142.11M and just keeps getting smaller every quarter. Time and them doing nothing but collecting their huge salaries.

0 · Reply

ACInvestorBlog May. 22 at 1:39 PM

$PLRX on high alert for the coming sessions. Still under accumulation.

2 · Reply

ACInvestorBlog May. 21 at 3:53 PM

0 · Reply

ACInvestorBlog May. 18 at 5:33 PM

$PLRX took some for a swing trade. Unusual buy block today. Company will participate in a fireside chat tomorrow at RBC Capital Markets Global Healthcare Conference.

1 · Reply

ACInvestorBlog May. 18 at 4:01 PM

$PLRX unusual block today and unusual tutes disclose last week 🤔

0 · Reply

StockTwitsGhost May. 15 at 4:44 PM

$PLRX $IRWD What do Ironwood Pharmaceuticals and Pliant Therapeutics have in common? Different science, different stories…same end result for shareholders: long-term shareholder destruction and underperformance, fading conviction, and charts that just won’t stop grinding lower. Different names, same question, what is the common theme? 📉🗑️

1 · Reply

focafoca99 May. 15 at 3:56 PM

$PLRX named its CEO Bernard Coulie as chair of Atisama board as the company advances its Phase 1 RB042 trial.

0 · Reply

GangsterX May. 14 at 4:11 PM

$PLRX Filled 1.17 Medium Size Thong ... this is a waiting game and it could take 4-6 months for it to Pop . I think they will acquire an asset. It cant sit like this forever with huge cash. Buy and Hold 4-6 months. I think Max 6 months.

0 · Reply

SQUEAKSBANDIT May. 13 at 8:01 PM

$PLRX i'd re-enter if i believed the board was willing to sell to tang, but i don't wanna take a two+ year journey while these guys draw salaries burn$ on the early stage assets and likely ask permission for a reverse (if they haven't already)

0 · Reply

THSSKS May. 13 at 2:01 PM

$PLRX this has a bad pipeline but I’ll rebuy between .90-$1 if it gets there. Bad pipeline and big ATM/ shelf might hold it back. I got a proxy to vote last week even though I sold last month but I’d vote no to anything they wanted. Just sell the company. Management gambling a couple hundred million on a phase 1 long shot

0 · Reply

SuperGreenToday May. 12 at 11:14 PM

$PLRX Share Price: $1.18 Contract Selected: Oct 16, 2026 $0.5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.28 – $0.34 Potential Upside: 54% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SQUEAKSBANDIT Apr. 30 at 1:10 PM

$PLRX is there any indication that tang will make an offer to the board and if he does, any indication that they will negotiate with him? or are they set on playing out the next few years working on these very early stage assets?

1 · Reply

focafoca99 Apr. 30 at 1:01 PM

$PLRX Pliant dosed the first participant in the Phase 1b FORTIFY indication expansion study.

0 · Reply

SQUEAKSBANDIT Apr. 28 at 9:27 PM

$PLRX i've been away for a few did the poison pill expire or was it renewed

1 · Reply

THSSKS Apr. 24 at 4:12 PM

$PLRX the pipeline sucks. That’s the problem. Too much competition with their treatment. Management is intent on blowing hundreds of millions on a long shot and offerings too.

1 · Reply

Market Cap	72.45M
Revenue (ttm)	0.00
Net Income (ttm)	-149.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	702,100
Avg Vol	452,712
Day's Range	N/A - N/A
Shares Out	61.92M
Stochastic %K	87%
Beta	1.21
Analysts	Hold
Price Target	$2.50